icotrokinra hydrochloride - Profile
✉ Email this page to a colleague
What are the generic sources for icotrokinra hydrochloride and what is the scope of freedom to operate?
Icotrokinra hydrochloride
is the generic ingredient in one branded drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Icotrokinra hydrochloride has eighty-two patent family members in thirty-three countries.
Summary for icotrokinra hydrochloride
| International Patents: | 82 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for icotrokinra hydrochloride
Generic Entry Date for icotrokinra hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for icotrokinra hydrochloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
